Pfizer's Paxlovid receives full FDA approval for high-risk COVID treatment.

The FDA has granted full approval to Pfizer's Covid antiviral pill, Paxlovid, for adults who are at high risk of getting severely sick with the virus. Paxlovid is specifically advised for the treatment of mild to moderate Covid in adults older than 50 and people who suffer from certain medical conditions that place them at a higher risk of ending up in the hospital or dying from Covid. The treatment consists of two medications: nirmatrelvir and ritonavir. Both Pfizer and the FDA view the treatment as an important complementary tool to vaccination that can help high-risk Americans manage their Covid infections and ultimately save lives.